Inventiva to Participate in Four Upcoming March Investor Conferences

Core Viewpoint - Inventiva is actively engaging with investors through participation in multiple healthcare conferences in March 2026, showcasing its focus on developing a treatment for metabolic dysfunction-associated steatohepatitis (MASH) [1][2]. Group 1: Upcoming Investor Events - The company will participate in the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, with a fireside chat scheduled for March 2 at 10:30 am EST in Boston, Massachusetts [1]. - Inventiva will also be present at the Leerink Global Healthcare Conference from March 9-11, 2026, with a presentation on March 10 at 10:00 am EDT in Miami, Florida [1]. - Additionally, the company will take part in the Barclays 28th Annual Global Healthcare Conference from March 10-12, 2026, with a fireside chat on March 11 at 11:00 am EDT in Miami, Florida [1]. - The UBS Biotech Conference: Catalyst for Change will also feature Inventiva from March 8-10, 2026, in Miami, Florida [1]. Group 2: Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing an oral small molecule therapy for MASH, currently evaluating lanifibranor in a pivotal Phase 3 clinical trial [2]. - The company is publicly listed on Euronext Paris (ticker: IVA) and the Nasdaq Global Market in the United States (ticker: IVA) [3].